Apixaban for Cancer-Associated Venous Thromboembolism. Reply.

Suppr

超能文献

作者信息

Mahé Isabelle, Carrier Marc, Laporte Silvy

机构信息

Université Paris Cité, Paris.

Ottawa Hospital Research Institute, Ottawa.

出版信息

N Engl J Med. 2025 Jul 17;393(3):311-312. doi: 10.1056/NEJMc2506526.

DOI:10.1056/NEJMc2506526

PMID:40673596

Abstract

摘要

相似文献

Apixaban for Cancer-Associated Venous Thromboembolism. Reply.

N Engl J Med. 2025 Jul 17;393(3):311-312. doi: 10.1056/NEJMc2506526.

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.阿哌沙班与达肝素治疗癌症相关性静脉血栓栓塞症的疗效和安全性：系统评价和荟萃分析。

Medicina (Kaunas). 2023 Oct 20;59(10):1867. doi: 10.3390/medicina59101867.

Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.口服直接Xa因子抑制剂与依诺肝素用于髋或膝关节置换术后血栓预防：系统评价、传统Meta分析、剂量反应Meta分析和网状Meta分析。

Thromb Res. 2015 Dec;136(6):1133-44. doi: 10.1016/j.thromres.2015.10.009. Epub 2015 Oct 20.

Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.与急性静脉血栓栓塞症治疗相关的临床和安全性结局：系统评价和荟萃分析。

JAMA. 2014 Sep 17;312(11):1122-35. doi: 10.1001/jama.2014.10538.

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.阿哌沙班预防癌症患者静脉血栓栓塞症。

N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4.

Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.阿哌沙班与利伐沙班预防静脉血栓栓塞症患者复发性静脉血栓栓塞和不良出血事件的有效性及安全性：一项基于人群的回顾性队列分析。

Lancet Haematol. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14.

A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism.阿哌沙班在预防和治疗癌症相关静脉血栓栓塞症中的系统评价。

J Am Pharm Assoc (2003). 2021 Sep-Oct;61(5):e26-e38. doi: 10.1016/j.japh.2021.06.005. Epub 2021 Jun 11.

Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.直接口服抗凝剂治疗癌症患者静脉血栓栓塞症：系统评价和网络荟萃分析。

Support Care Cancer. 2022 Dec;30(12):10407-10420. doi: 10.1007/s00520-022-07433-4. Epub 2022 Nov 1.

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.延长低剂量阿哌沙班用于癌症相关静脉血栓栓塞症

N Engl J Med. 2025 Apr 10;392(14):1363-1373. doi: 10.1056/NEJMoa2416112. Epub 2025 Mar 29.

Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.阿哌沙班和达肝素治疗活动性恶性肿瘤相关静脉血栓栓塞症。ADAM VTE 试验。

Thromb Haemost. 2017 Oct 5;117(10):1952-1961. doi: 10.1160/TH17-03-0193. Epub 2017 Aug 24.

引用本文的文献

Long term anticoagulation for Catheter-Related deep vein thrombosis of the upper extremities in women with cancer: retrospective analysis of effectiveness and safety outcomes.癌症女性上肢导管相关深静脉血栓形成的长期抗凝治疗：有效性和安全性结果的回顾性分析

J Thromb Thrombolysis. 2025 Sep 26. doi: 10.1007/s11239-025-03182-3.

Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.低剂量与全剂量直接口服抗凝剂用于静脉血栓栓塞症的延长治疗：一项系统评价和荟萃分析

Cardiovasc Drugs Ther. 2025 Aug 22. doi: 10.1007/s10557-025-07759-1.

Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.静脉血栓栓塞症患者中，延长减量与全剂量使用Xa因子抑制剂治疗的比较：一项采用GRADE评估的随机对照试验系统评价与荟萃分析

Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 22. doi: 10.1007/s00210-025-04388-1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验